BMY

Today, 12:04 PMBristol Myers beats Q3 2026 estimates and raises 2026 EPS guidance to $6.35–$6.55 as Eliquis and new launches drive growth

Peers: MRK PFE AZN NVS ABBV AMGN GILD JNJ GSK LLY

| Held by: VTI SCHD VOO IVV SPY VTV XLV VYM HDV HDV

Scroll to Statements

Index	S&P 500
Market Cap	124.17B
Enterprise Value	158.15B
Income	9.28B
Sales	49.20B
Book/sh	10.92
Cash/sh	5.42
Dividend Est.	2.54 (4.18%)
Dividend TTM	2.52 (4.15%)
Dividend Ex-Date	Oct 02, 2026
Dividend Gr. 3/5Y	4.37% 6.24%
Payout	71.98%
Employees	32500
IPO	Jul 05, 1929

P/E	13.39
Forward P/E	9.18
PEG	-
P/S	2.52
P/B	5.56
P/C	11.22
P/FCF	10.85
EV/EBITDA	8.24
EV/Sales	3.21
Quick Ratio	1.38
Current Ratio	1.53
Debt/Eq	2.02
LT Debt/Eq	1.96
Option/Short	Yes / Yes

EPS (ttm)	4.54
EPS next Y	6.62
EPS next Q	1.62
EPS this Y	3.28%
EPS next Y	4.28%
EPS next 5Y	-4.78%
EPS past 3/5Y	5.47% -
Sales past 3/5Y	1.45% 2.54%
EPS Y/Y TTM	83.17%
Sales Y/Y TTM	3.13%
EPS Q/Q	49.96%
Sales Q/Q	6.22%
Earnings	Oct 29 BMO
EPS/Sales Surpr.	22.86% 2.72%

Insider Own	0.32%
Insider Trans	-0.10%
Inst Own	85.29%
Inst Trans	0.47%
ROA	10.18%
ROE	46.70%
ROIC	14.03%
Gross Margin	66.64%
Oper. Margin	32.35%
Profit Margin	18.87%
SMA20	1.10%
SMA50	-3.28%
SMA200	1.45%
Trades

Shs Outstand	2.04B
Shs Float	2.04B
Short Float	2.45%
Short Ratio	4.32
Short Interest	49.95M
52W High	68.64 -11.44%
52W Low	42.52 42.96%
Volatility	2.22% 2.73%
ATR (14)	1.66
RSI (14)	48.45
Beta	0.20
Rel Volume	0.84
Avg Volume	11.57M
Volume	8,754,182

Perf Week	-3.52%
Perf Month	-2.59%
Perf Quarter	-6.93%
Perf Half Y	0.32%
Perf YTD	12.69%
Perf Year	42.69%
Perf 3Y	19.14%
Perf 5Y	4.08%
Perf 10Y	19.19%
Recom	2.48
Target Price	65.13
Prev Close	60.57
Price	60.78
Change %	0.35%

ConsensusModerate Buy

Avg. Price Target

$60.44

Implied Upside

-0.6%

Analysts16incl. previous ratings

Rating Distribution7 Buy · 9 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 05, 2026	Downgrade	LLeerink Partners	Outperform → Market Perform	$59	-2.9%
Aug 05, 2026	Upgrade	AArgus	Hold → Buy	$75	+23.4%
Feb 25, 2026	Initiated	RRBC Capital Mkts	Sector Perform	$60	-1.3%
Feb 20, 2026	Initiated	BBarclays	Overweight	$75	+23.4%
Jan 07, 2026	Upgrade	UUBS	Neutral → Buy	$65	+6.9%
Dec 15, 2025	Upgrade	BBofA Securities	Neutral → Buy	$61	+0.4%
Dec 12, 2025	Upgrade	GGuggenheim	Neutral → Buy	$62	+2.0%
Nov 13, 2025	Initiated	BScotiabank	Sector Perform	$45	-26.0%
Aug 05, 2025	Downgrade	DDaiwa Securities	Outperform → Neutral	$42	-30.9%
Apr 22, 2025	Initiated	PPiper Sandler	Overweight
Apr 22, 2025	Initiated	CCantor Fitzgerald	Neutral	$55	-9.5%
Dec 16, 2024	Upgrade	JJefferies	Hold → Buy	$70	+15.2%
Dec 10, 2024	Resumed	BBofA Securities	Neutral	$63	+3.6%
Nov 15, 2024	Initiated	WWolfe Research	Peer Perform
Nov 13, 2024	Upgrade	DDaiwa Securities	Neutral → Outperform
Nov 12, 2024	Upgrade	LLeerink Partners	Market Perform → Outperform	$73	+20.1%
Oct 25, 2024	Downgrade	CCitigroup	Buy → Neutral	$75 → $55	-9.5%
Oct 17, 2024	Initiated	BBernstein	Mkt Perform	$56	-7.9%
Jul 29, 2024	Downgrade	BBarclays	Overweight → Equal Weight	$41	-32.5%
Mar 11, 2024	Downgrade	SSociete Generale	Buy → Hold

Today 12:46PM	Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue (Bloomberg)
12:06PM	Bristol Myers Still Confident in Autoimmune Therapy After Patient Death (The Wall Street Journal)
10:50AM	Bristol Myers Squibb Reports 7% Rise in Q3 Revenue to $13.07 Billion and Raises 2026 Sales Outlook (InvestorsHub)
10:43AM	Anthropic Announced New Achievements in Drug Research and Lab Work. An Expert Says AI is 'Changing the Medical Field.' (International Business Times)
10:39AM	Bristol Myers Beats And Raises For A Third Straight Quarter, But Slowing Growth Drivers And The Eliquis Cliff Keep The Debate Alive (Earnings Whispers)
08:56AM	Loading…
08:56AM	Bristol Myers Slips: Opdivo Sales Come Up Short, Earnings Guidance Cut (Investor's Business Daily)
07:13AM	Bristol Myers Squibb Raises Outlook as Quarterly Revenue Rises (The Wall Street Journal)
07:06AM	Bristol Myers: Q3 Earnings Snapshot (Associated Press)
06:59AM	Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 (Business Wire)
Oct-26-26 09:59AM	Another autoimmune CAR-T death; Treasury zeroes in on China deals (BioPharma Dive)
09:50AM	The excitement around Moderna's cancer vaccine is cooling. Here's why. (MarketWatch)
06:39AM	Pathos AI completes $237m Series E round to expand oncology pipeline (Hospital Management)
03:30AM	Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study (Business Wire)
Oct-23-26 04:22PM	Patient Death Reported in Bristol Myers Squibb Autoimmune Study (The Wall Street Journal)
03:48PM	BMY Stock Falls 2% After Patient Death In Early Multiple Sclerosis CAR T Trial (Stocktwits)
10:30AM	Loading…
10:30AM	Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026 (Business Wire)
09:00AM	Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development (Reuters)
09:00AM	Tempus Expands Strategic Collaboration with Bristol Myers Squibb (Business Wire)
09:00AM	Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimers Disease and Other Neurological Conditions (Business Wire)
07:30AM	Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study (Business Wire)
Oct-21-26 11:22AM	Bristol Myers Must Prove Its Guidance Raise Was Real As Eliquis Tailwind Arrives (Earnings Whispers)
05:30AM	Healthcare Stocks Are Rallying, and Flashing a Warning for the Rest of the Market (The Wall Street Journal)
Oct-20-26 04:30PM	Bristol Myers Squibb Co. stock outperforms competitors on strong trading day (MarketWatch)
03:25AM	Investors Are Turning Cautious on Big Pharma as Earnings Season Unfolds (The Wall Street Journal)
Oct-19-26 06:59AM	Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026 (Business Wire)
Oct-16-26 08:53PM	When Amgen's Forecast And Chart Say The Same Thing, Pay Attention (Trefis)
08:37PM	Gileads HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next? (Trefis)
08:13PM	Is Amgen Stock Increasing Your Market Risk? (Trefis)
Oct-15-26 03:46PM	How Has Merck's Story Changed? (Trefis)
08:55AM	Hype vs. reality: What pharmas hottest R&D bets have actually proved (Pharma Voice)
05:45PM	Loading…
Oct-14-26 05:45PM	What Could Send Regeneron Stock Higher? (Trefis)
Oct-13-26 07:48PM	Is Amgen Stock Worth More Than Its Competitors? (Trefis)
03:59PM	What Does Bristol-Myers Squibb Offer That Pfizer Does Not? (Trefis)
11:24AM	Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. (Barrons.com)
08:30AM	Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation (ACCESSWIRE)
Oct-12-26 01:20PM	BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses (Stocktwits)
01:05PM	Bristol Myers falls 3% despite positive cancer drug trial results (Proactive)
11:54AM	BMS gains two pivotal trial wins in lung disease and rare cancer (Clinical Trials Arena)
11:35AM	Bristol Myers dips on confounding lung drug results (BioPharma Dive)
10:15AM	Bristol Myers Stock Is Rising on a Double Dose of Good News (Barrons.com)
09:37AM	Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On One (Investor's Business Daily)
08:42AM	Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results (InvestorsHub)
08:40AM	Bristol Myers Squibb Shares Jump 6.5% Following Positive Phase 3 Trial Results for Two Therapies (InvestorsHub)
07:55AM	Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating (Investing.com)
07:36AM	Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes (Investing.com)
06:55AM	Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBios Radiopharmaceutical Therapy, in Patients with GEP-NETs (Business Wire)
06:50AM	Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint (Business Wire)
Oct-11-26 09:22PM	SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH (Stocktwits)
Oct-09-26 08:47PM	Why Is Everyone Ignoring Gilead Stock's High Cash Yield? (Trefis)
02:12PM	Does The Move In Merck Stock Change Anything? (Trefis)
Oct-08-26 08:36PM	Should You Be Worried About Pfizer Stock? (Trefis)
08:19PM	What Is Going On With Regeneron Stock? (Trefis)
12:55PM	BMSs Zenbexus meets PFS endpoint in pivotal multiple myeloma trial (Clinical Trials Arena)
09:03AM	What Would It Take For Amgen Stock To Move Higher? (Trefis)
06:59AM	Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3... (Business Wire)
Oct-07-26 07:14PM	Is Exelixis Stock Engineered To Make You Money? (Trefis)
11:21AM	Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial (BioPharma Dive)
Oct-05-26 09:58AM	Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt (Investing.com)
09:44AM	Microsoft upgraded, HubSpot downgraded: Wall Street's top analyst calls (The Fly)
Oct-02-26 06:27AM	How Has Pfizer's Story Changed? (Trefis)
Oct-01-26 06:59AM	Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement (Business Wire)
Sep-30-26 05:32PM	U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibbs CAMZYOS (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients* (Business Wire)
01:10PM	This Pharma Giant Has The Right Medicine For Income Investors (Investor's Business Daily)
12:22PM	Bristol Myers trial revisions shake confidence in new class of fibrosis drugs (BioPharma Dive)
11:34AM	PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer (TIKR)
11:29AM	Are You Overpaying For Pfizer Stock Versus Its Rivals? (Trefis)
10:43AM	What Is Merck Stock's Biggest Opportunity? (Trefis)
Sep-28-26 02:08PM	What Are Merck Stock Investors Overlooking? (Trefis)
07:29AM	Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa (ACCESSWIRE)
06:44AM	FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals (Stocktwits)
Sep-25-26 01:03PM	Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? (Trefis)
10:00AM	Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma (Business Wire)
Sep-24-26 06:41PM	Acadia Pharmaceuticals Fell 19% Today. Heres Where the Stock Could Go in 2026 (TIKR)
03:55PM	Top Stock Reports for Tesla, Bank of America & Coca-Cola (Zacks)
07:29AM	Leveraging Brazil's Health Networks for Early Lung Cancer Detection (ACCESSWIRE)
Sep-23-26 01:18PM	What Is AbbVie No Longer Telling You? (Trefis)
12:37PM	What Is The Best Case For Pfizer Stock? (Trefis)
Sep-22-26 10:47AM	Eli Lilly Breaks Ground on $6.5B Generation Park Facility (CRE Daily)
09:50AM	Could You Have Seen Merck Stock's Pipeline Run Coming? (Trefis)
07:29AM	Transforming Lung Cancer Care & Early Detection in Tanzania (ACCESSWIRE)
Sep-21-26 10:17AM	What Would It Take For Pfizer To Cut Its Dividend? (Trefis)
Sep-18-26 02:09PM	Merck Stock Nearly Doubled Without A Change In Its Revenue Growth (Trefis)
06:59AM	Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 (Business Wire)
06:24AM	Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug (BioPharma Dive)
Sep-17-26 08:11AM	What Happens To AbbVie Stock If SKYRIZI Slows Down? (Trefis)
07:29AM	How Can Lung Cancer Screening in India Reflect Risk Beyond Smoking? (ACCESSWIRE)
06:59AM	Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years (Business Wire)
Sep-16-26 04:12PM	Is Pfizer's New Business Big Enough To Carry The Old One? (Trefis)
10:37AM	AstraZeneca shares oversold after trial flops and merger talk, says UBS (Proactive)
06:59AM	Bristol Myers Squibb Announces Dividend (Business Wire)
Sep-15-26 08:44PM	Merck Stock: Is The $70 Billion Pipeline Worth the Premium? (Trefis)
Sep-14-26 03:57PM	Why Is Pfizer Stock Paying You So Much To Wait? (Trefis)
03:59AM	Big Pharma Is Pouring Billions Into China's Biotechs (Barrons.com)
Sep-11-26 03:11PM	Is AbbVie Stock Actually Overpriced? (Trefis)
Sep-10-26 01:14PM	'Miracle' Cancer Drug Sets Revolution Medicines Up for More Market Gains (Barrons.com)
11:05AM	Why Has AbbVie Gone Quiet About Humira? (Trefis)
Sep-09-26 10:32PM	Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes (Trefis)
07:29AM	National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort (ACCESSWIRE)
03:00AM	A new immuno-oncology play raises $225M for a next-generation drug (BioPharma Dive)
Sep-08-26 01:08PM	Is AbbVie Stock Too Reliant On Skyrizi? (Trefis)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gallman Cari	EVP, General Counsel	Oct 02 '26	Option Exercise	0.00	4,559	0	18,208	Oct 05 04:18 PM
Massacesi Cristian	EVP,Chief Med Offr,Head of Dev	Sep 09 '26	Sale	64.57	6,249	403,498	18,748	Sep 10 04:37 PM
Massacesi Cristian	Officer	Sep 09 '26	Proposed Sale	64.57	6,249	403,498		Sep 09 10:27 AM
Short Bartie Wendy	EVP, Corporate Affairs	Sep 01 '26	Option Exercise	66.92	1,236	82,713	13,317	Sep 03 04:12 PM
Holzer Phil M	SVP and Controller	Aug 25 '26	Sale	67.50	500	33,750	16,862	Aug 26 04:17 PM
Holzer Phil M	Officer	Aug 25 '26	Proposed Sale	67.50	500	33,750		Aug 25 11:03 AM
Massacesi Cristian	EVP,Chief Med Offr,Head of Dev	Aug 01 '26	Option Exercise	0.00	51,172	0	51,172	Aug 04 04:10 PM
Gallman Cari	EVP, General Counsel	Aug 01 '26	Option Exercise	0.00	1,061	0	14,192	Aug 04 04:07 PM
Haller Julia A	Director	Jun 15 '26	Option Exercise	53.76	20,460	1,099,930	34,079	Jun 16 04:07 PM
Short Bartie Wendy	EVP, Corporate Affairs	Jun 03 '26	Option Exercise	0.00	8,040	0	15,957	Jun 05 04:10 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	May 01 '26	Option Exercise	0.00	1,373	0	20,508	May 05 05:11 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Apr 01 '26	Option Exercise	0.00	3,307	0	27,580	Apr 02 04:30 PM
Elkins David V	EVP, Chief Financial Officer	Apr 01 '26	Sale	61.67	30,000	1,850,016	159,248	Apr 02 04:29 PM
Elkins David V	Officer	Apr 01 '26	Proposed Sale	61.69	30,000	1,850,645		Apr 01 04:32 PM
Short Bartie Wendy	EVP, Corporate Affairs	Mar 10 '26	Option Exercise	0.00	5,883	0	10,952	Mar 12 04:22 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Mar 10 '26	Option Exercise	0.00	25,501	0	39,120	Mar 12 04:21 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '26	Option Exercise	0.00	17,501	0	31,600	Mar 12 04:20 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Mar 10 '26	Option Exercise	0.00	25,892	0	44,330	Mar 12 04:19 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '26	Option Exercise	0.00	24,071	0	26,104	Mar 12 04:18 PM
Holzer Phil M	SVP and Controller	Mar 10 '26	Option Exercise	0.00	6,191	0	20,475	Mar 12 04:17 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '26	Option Exercise	0.00	8,192	0	12,217	Mar 12 04:17 PM
Gallman Cari	EVP, General Counsel	Mar 10 '26	Option Exercise	0.00	6,980	0	17,039	Mar 12 04:16 PM
Poole Ahn Amanda	EVP, Chief People Officer	Mar 10 '26	Option Exercise	0.00	6,436	0	10,718	Mar 12 04:15 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '26	Option Exercise	0.00	71,537	0	47,382	Mar 12 04:14 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '26	Option Exercise	0.00	62,982	0	222,773	Mar 12 04:13 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '26	Option Exercise	0.00	2,543	0	22,261	Feb 03 04:40 PM
Hickey Benjamin	President, RayzeBio Org.	Feb 01 '26	Option Exercise	0.00	10,079	0	18,868	Feb 03 04:39 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '25	Option Exercise	0.00	2,964	0	2,964	Nov 04 05:18 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Nov 01 '25	Option Exercise	0.00	6,281	0	22,383	Nov 04 05:15 PM
Shanahan Karin	EVP, Chief Supply Chain & Ops	Nov 01 '25	Option Exercise	0.00	6,281	0	20,078	Nov 04 05:13 PM

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

CEO & ChairmanDr. Christopher S. Boerner Ph.D.

Executive VP & CFOMr. David V. Elkins

Executive VP and Chief Digital & Technology OfficerMr. Greg Meyers

Executive VP & Chief Commercialization OfficerMr. Adam Lenkowsky

Executive VPMr. Cristian Massacesi M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bristol-Myers Squibb Co

Upgrade your Finviz experience